Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pharma News and Updates for BMS, Mirati, Roche, Dermavant, Merck

Bristol-Myers Squibb’s Opdivo Approval; Mirati’s KRAS-inhibitor Adagrasib; J&J and Legend Biotech’s CAR-T Carvykti Approval; Roche’s Glofitamab; Arena Pharma’s Etrasimod Phase 3 Trials; FDA Approves Dermavant’s Vtama; FDA Approves Novartis’ Cell Therapy; NICE Approves Merck’s Keytruda

Bristol-Myers Squibb’s Opdivo Gets FDA Approval for Esophageal Cancer The FDA has approved two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously untreated advanced Esophageal Cancer, encroaching on the territory belonging to Merck & Co’s rival Keytruda. The latest approvals are for Opdivo (nivolumab) in combination with chemotherapy or BMS’ CTLA4 inhibitor Yervoy (ipilimumab) as first-line therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) that cannot be treated surgically. Both regimens improved overall survival compared to chemotherapy alone in the Phase 3 study, which was reported to be t...

Explore More...

recent-pharma-happenings-for-nestle-gsk-astrazeneca

Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial

recent-pharma-news-and-updates-for-moderna-freenome

Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

Latest pharma happenings for Roche and Secura Bio

FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target

MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic’s IMU-838 promising results

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid’s DMD gene therapy trial

Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai’s Collaboration; A new study on averting heart attack

Pharma happenings and latest COVID-19 News

AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership

Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update

Pharma News | COVID-19 News | Cancer News

Merck, Dewpoint’s HIV Pipeline; Pfizer, BioNTech ‘s COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer

Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial

Moderna’s COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates

Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis

FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target

MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic’s IMU-838 promising results

More Views & Analysis

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid’s DMD gene therapy trial

Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai’s Collaboration; A new study on averting heart attack

AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership

Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update

Merck, Dewpoint’s HIV Pipeline; Pfizer, BioNTech ‘s COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer

Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates

Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies

Subscribe to our Updates

Daily

Weekly

Monthly